Effects of neferine on CCL5 and CCR5 expression in SCG of type 2 diabetic rats.
Chemokines and their receptors have the key role in inflammatory responses. The phenomenon of low grade inflammation is associated with the development of type 2 diabetes. Postprandial hyperglycemia increases the systemic inflammatory responses, which promotes the development of type 2 diabetic associating autonomic nervous injuries or cardiovascular disease. Neferine is a bisbenzylisoquinline alkaloid isolated from a Chinese medicinal herb. The objectives of this study will examine the CCL5 and CCR5 expression in the superior cervical ganglion (SCG) of type 2 diabetic rats. The effects of neferine on the expression of CCL5 and CCR5 mRNA and protein in the superior cervical ganglion (SCG) of type 2 diabetic rats will also be observed. The studies showed that in type 2 diabetic rats, body weight, blood pressure, heart rates, fasting blood glucose, insulin, total cholesterol and triglyceride were enhanced and high density lipoprotein was decreased, and CCL5 and CCR5 expression levels in the SCG of type 2 diabetic rats were up-regulated. In type 2 diabetic rats treated with neferine, body weight, blood pressure, fasting blood glucose, insulin, total cholesterol and triglyceride were decreased and high density lipoprotein was increased. The elevated expressions of CCL5 and CCR5 in SCG were decreased after type 2 diabetic rats treated with neferine. The motor nerve conduction velocity (MNCV) in diabetic rats treated with neferine group showed a significantly increment in comparison with that in type 2 diabetic group. Neferine can decrease the expression of CCL5 and CCR5 in the SCG and reduce the SCG neuronal signaling mediated by CCL5 and CCR5 in regulating diabetic cardiovascular autonomic complications.
Department of Physiology, Nanchang, Jiangxi 330006, PR China.
Guilin
G
Li
Hong
H
Xu
Shuanghua
S
Zhu
Wenyuan
W
Xu
Shulan
S
Qin
Shuangmei
S
Liu
Guihua
G
Tu
Haiying
H
Peng
Shuyi
S
Qiu
Shicheng
S
Yu
Qicheng
Q
Zhu
Bo
B
Fan
Chaoran
C
Zheng
Guodong
G
Li
Shangdong
S
Liang
D000704:Analysis of Variance; D000818:Animals; D044182:Benzylisoquinolines / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D018946:Chemokine CCL5 / Q000235:genetics / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000473:pathology*; D004195:Disease Models, Animal; D005215:Fasting / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D007004:Hypoglycemic Agents / Q000378:metabolism; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism / Q000187:drug effects; D008075:Lipoproteins, HDL / Q000378:metabolism; D008297:Male; D009431:Neural Conduction / Q000187:drug effects; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D019713:Receptors, CCR5 / Q000235:genetics / Q000378:metabolism*; D000077154:Rosiglitazone; D017783:Superior Cervical Ganglion / Q000187:drug effects*; D045162:Thiazolidinediones / Q000494:pharmacology
D044182:Benzylisoquinolines; D001786:Blood Glucose; D018946:Chemokine CCL5; D007004:Hypoglycemic Agents; D007328:Insulin; D008075:Lipoproteins, HDL; D012333:RNA, Messenger; D019713:Receptors, CCR5; D045162:Thiazolidinediones; D000077154:Rosiglitazone; C057222:neferine